Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Loading...
Community
/
United States
/
Pharmaceuticals & Biotech
/
Hoth Therapeutics
HOTH
Hoth Therapeutics
Sponsored
content by Hoth Therapeutics
100% Patient Improvement in trial puts this $16M Biotech on the radar
JO
Jolt_Communications
Not Invested
Community Contributor
Published
01 Sep 25
Updated
02 Sep 25
1
Set Fair Value
0
votes
Share
Jolt_Communications
's Fair Value
US$5.30
78.1% undervalued
intrinsic discount
02 Sep
US$1.16
1Y
67.2%
7D
-7.2%
Loading
1Y
67.2%
7D
-7.2%
Author's Valuation
US$5.3
78.1% undervalued
intrinsic discount
Jolt_Communications's Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
Jolt_Communications
's
Fair Value
US$5.3
78.1% undervalued
intrinsic discount
Future estimation in
5 Years
time period
Past
Future
-12m
0
2017
2019
2021
2023
2025
2027
2029
2030
Revenue US$0
Earnings US$0
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
95.27%
Pharma revenue growth rate
0.57%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.78%
Calculation
US$0
Earnings '30
x
20.00x
PE Ratio '30
=
US$0
Market Cap '30
US$0
Market Cap '30
/
49.23m
No. shares '30
=
US$0
Share Price '30
US$0
Share Price '30
Discounted to 2025 @ 15.00% p.a.
=
US$0
Fair Value '25
